A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

July 4, 2024

Study Completion Date

July 4, 2024

Conditions

Carcinoma, Non-Small-Cell Lung

Trial Locations (7)

Research Site, Kuwait City

Research Site, Doha

Research Site, Dammam

Research Site, Jeddah

Research Site, Riyadh

Research Site, Abu Dhabi

Research Site, Al Ain City